Program
HB0017
A development code. Also written as “HB0017 Injection”, “HB0017 Q4W” and “HB0017 Q8W”.
Its studies are mostly in Psoriasis, led by Huabo Biopharm.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Huabo Biopharm | 51 open or running | phase 3since Jun 18, 2024 | Aug 4, 2020 | Dec 31, 2026phase 1 · NCT07920861 |
Also a collaborator on its studies: shanghai-huaota-biopharmaceutical-co-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 4, 2020First study: phase 1 study in Healthy SubjectsFirst studyNCT04505033 · 40 enrolled · New Zealand
- Aug 31, 2022Phase 2 study in Plaque PsoriasisNCT05531682 · 160 enrolled · China
- Jun 18, 2024Phase 3 study in PsoriasisNCT06477237 · 408 enrolled · China
- Sep 9, 2024Phase 2 study in PsoriasisNCT06592274 · 206 enrolled · China
- Oct 21, 2026Phase 1 study in PsoriasisNCT07920861 · 90 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 1 study in PsoriasisNCT07920861
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07920861Psoriasis · China | 1 | Recruiting | Dec 31, 2026 | 90 |
| NCT06592274Psoriasis · China | 2 | Completed | Apr 30, 2025 | 206 |
| NCT06477237Psoriasis · China | 3 | Completed | Nov 15, 2024 | 408 |
| NCT05531682Plaque Psoriasis · China | 2 | Completed | May 23, 2023 | 160 |
| NCT04505033Healthy Subjects · New Zealand | 1 | Completed | Jan 2, 2021 | 40 |
How it is read
Names in the registry
- “HB0017”, 5 entries
- “HB0017 Injection”, 1 entry
- “HB0017 Q4W”, 1 entry
- “HB0017 Q8W”, 1 entry
Codes read as this program: HB0017.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.